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Abstract 
Intra-abdominal fibromatosis is a rare benign 
tumor which can pose challenges in its 
management because of its local aggressive 
invasion and propensity for high recurrence. 
Here we report the case of a young woman who 
presented with a large intra-abdominal tumor 
with bilateral ureteric compression. This case 
highlights the risks of surgical intervention, the 
limitations of radiotherapy and subsequent 
complications that can develop over the years in 
such patients. 
1M.S.Ramaiah Medical College, Bangalore 
Introduction 
Deep fibromatosis or aggressive 
fibromatosis (also called desmoid tumor 
or musculo-aponeurotic fibromatosis) is 
a rare, locally aggressive, monoclonal 
fibroblastic proliferation arising from the 
musculo-aponeurosis. It is characterized 
by local invasion and a high rate of local 
recurrence, but without any metastatic 
potential. The tumor, lacking a capsule, 
infiltrates along fascial planes and 
invades adjacent neurovascular 
structures. 
Fibromatoses are rare, representing 
<3% of all soft tissue tumors, with an 
estimated incidence of 2-4 new cases 
per million per year.1 Depending on their 
location, they are classified as extra-
abdominal, abdominal or intra-
abdominal, and the latter have been 
sub-classified further into mesenteric or 
pelvic fibromatosis. Fibromatosis is 
more frequently seen over the torso and 
the extremities. Between 37% and 50% 
of the aggressive cases occur in the 
abdominal region. They occur frequently 
between the ages of 25 and 35 years 
(range of 10-40 years) and are slightly 
more common in women than men 
(1.2:1). 
With their relentless infiltration of 
surrounding structures, often involving 
vital structures, they present 
management challenges that defy easy 
answers and usually require a multi-
modality approach. Herein we present a 
case report of a patient with intra-
abdominal fibromatosis who had a high 
morbidity both during surgery and the 
subsequent follow-up. This case 
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highlights the aggressive nature and 
malignant-like course of this disease. 
Case report   
A 25 year old woman with two children 
was evaluated in 2004 at a Cancer 
Institute for an abdominal mass of two 
years duration. Her abdominal 
ultrasound was reported as a 
leiomyoma of the posterior wall of the 
uterus, with sarcomatous changes. Fine 
needle aspiration cytology had revealed 
a benign spindle cell neoplasia. 
Subsequent laparotomy findings 
demonstrated a stony hard mass of 20 x 
15 cm arising from the right broad 
ligament and pelvic bone and infiltrating 
the right lateral pelvic wall and sacrum. 
Due to adherence of the tumor to the 
surrounding structures, any further 
procedure was not pursued. She had 
refused radiotherapy and further follow-
up. 
She presented to us in June 2006 with 
abdominal discomfort due to the mass, 
which was gradually increasing in size. 
There was no history of abdominal pain 
or bowel, bladder or menstrual 
disturbances. 
 
Figure 1. Preoperative extent of the 
abdominal mass 
On examination, there was an irregular, 
fixed mass with varied consistency in 
the hypogastric, umbilical, right lumbar 
and right iliac areas corresponding to a 
uterine size of 28 gestational weeks 
(approximately 28 cm, Figure 1). The 
cervix was attenuated by the mass. 
Uterus was not felt separately.  
Investigations 
Ultrasound demonstrated a tumor with 
solid and cystic components. Uterus and 
ovaries were not visualized. There was 
bilateral hydronephrosis. Subsequent 
CT scan reported a tumor with both 
solid and cystic areas not arising from 
the bone; the tumor was only partly 
separated from the iliopsoas. Uterus 
was deviated to the left; both ovaries 
were not visualized, and there was a 
moderate degree of bilateral 
hydronephrosis. 
Renal function tests were normal. 
Colonoscopy showed normal mucosa.   
 
Figure 2. Separation of the tumor 
from the abdominal wall during 
surgical debulking.  
In view of patient’s discomfort and 
bilateral hydronephrosis, she was taken 
up for laparotomy after adequate 
counseling. There was a 20 x 20 x 15 
cm bosselated mass of heterogeneous 
consistency and as we proceeded to 
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debulk the tumor, we saw it infiltrating 
the dome of the bladder, periosteum of 
the pubic arch, right iliopsoas, and 
sacrum. (Figure 2) 
In addition, the uterus was pushed to 
the left. The left fallopian tube and ovary 
were normal; right adnexal structures 
were not visualized. The tumor encased 
the small bowel, right ureter, right 
common iliac, and the external and 
internal iliac vessels. The tumor was 
removed from the posterior aspect of 
the symphysis pubis, iliac crest, anterior 
abdominal wall, and iliopsoas. 
Debulking necessitated hysterectomy as 
well as right ureteric resection and 
anastomosis, repair of the resected 
dome of bladder, and repair of small 
bowel injury. The posterior aspect of the 
tumor encasing right iliac vessels was 
not removed. During surgery, the patient 
was adequately transfused with packed 
red cells and fresh frozen plasma. 
Histopathological analysis of the tumor 
resulted in a diagnosis of fibromatosis, 
predominantly fibro-collagenous tissue 
with intervening benign spindle-shaped 
cells resembling myofibroblasts. (Figure 
3) 
 
Figure 3. Histopathology showing 
bland sheets of cells indicative of 
fibromatosis. 
Patient had a difficult post-operative 
period due to sepsis, which was 
managed medically. The patient refused 
radiotherapy for residual disease. She 
was discharged after three weeks in 
satisfactory condition with advice for 
regular follow-up. 
The patient was on irregular follow-up. 
In a visit in 2008, she had a hard, fixed 
right iliac fossa mass. Ultrasound 
showed a solid, hypo echoic mass of 
9.5×6.1 cm adherent to the right pelvic 
wall with mild bilateral pelvicalyceal 
dilatation of the kidneys. The right 
kidney was smaller and showed 
parenchyma thinning. In view of a large 
recurrent tumor within two years of 
surgery (Figure 4), she received 
external RT using 3-D CRT technique 
with 5000cGy/25 fractions/5 days per 
week. 
 
Figure 4. Recurrence of tumor 
observed during CT prior to 
radiotherapy 
The patient presented in 2010 with 
burning micturition and fecaluria. 
Abdominal examination showed that the 
tumor in the right iliac fossa had 
decreased, measuring about 5-6 cm. 
Ultrasound demonstrated a small right 
echogenic kidney with dependent debris 
in the urinary bladder. The post-void 
volume was 135 ml. Urine examination 
showed fecal matter. Renal function 
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tests were normal. The nature of the 
fistula was investigated. Intravenous 
urogram showed pooling of contrast in 
the region of the right iliac fossa on the 
delayed scan, and a vesico-ileal fistula 
was inferred. On cystoscopy, a fistulous 
opening of approximately 5 cm at the 8 
o’clock position was visualized near the 
bladder neck. The cystogram 
demonstrated the contrast entering the 
ascending colon; a diagnosis of vesico-
colonic fistula was made. Two options 
were discussed with the patient: 1) 
surgical intervention, which was 
predicted to have a very high morbidity 
due to the unresectability of the tumor; 
or 2) conservative management. A plan 
of regular follow-up with symptomatic 
treatment was agreed upon.  
This patient has been since seen 
irregularly. In August 2012 and again in 
May 2013, she presented with easy 
fatigability. She had a persistent hard 
mass of 6 cm-7 cm in the right iliac 
fossa. Ultrasound scan showed bilateral 
medical renal disease but renal function 
tests were normal. She was treated with 
antibiotics for her urinary tract infection 
and required blood transfusions for her 
symptomatic severe anemia during both 
of these visits.  
Discussion  
Intra-abdominal fibromatosis is a rare 
soft tissue tumor whose etiology 
remains elusive. Researchers have 
attributed various predisposing factors, 
including trauma, previous surgeries, 
estrogen exposure, and a genetic 
predisposition. The increased incidence 
in women of reproductive age suggests 
an association of this disease with the 
endogenous hormonal environment. 
Desmoids and Familial Adenomatous 
Polyposis (FAP) 
Familial adenomatous polyposis is an 
autosomal dominant condition in which 
numerous adenomatous polyps are 
seen in the colon and rectum. A variant 
of FAP, Gardner’s syndrome, presents 
with extracolonic manifestations like 
desmoid tumors, osteomas and 
epidermoid cysts along with a 
predisposition to thyroid and 
periampullary carcinomas.2 An 
association of intra-abdominal desmoids 
with familial adenomatous polyposis of 
the colon and Gardner’s syndrome has 
been well documented.  They occur 
more frequently in FAP patients, with an 
incidence of 3.5%-32%, and about 2% 
of patients presenting with desmoid 
tumor have FAP. The FAP patients with 
intra-abdominal desmoids present at a 
younger age, often before the fourth 
decade of life and are more likely to 
have advanced or complicated disease.3  
Mutations of the adenomatous polyposis 
coli (APC) gene are thought to be 
responsible for the development of FAP. 
In both FAP and non-FAP desmoid 
tumors, mutations of the APC gene on 
the long arm of chromosome 5 have 
been implicated. Desmoids occurring in 
FAP patients are often associated with 
germline mutations in the APC gene, 
whereas sporadic desmoids have 
somatic mutations in the APC gene or in 
the beta-catenin gene. In the cellular 
environment of these tumors, where 
either APC or beta-catenin is mutated, 
there is a loss of ability to degrade beta-
catenin, which accumulates before it 
translocates into the nucleus.4 Beta-
catenin subsequently activates the T-
cell factor, which in turn causes 
transcription of target genes. One of the 
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target genes for activation is 
cyclooxygenase-2. This gene’s activity 
contributes to tumorigenesis by 
inhibiting apoptosis, stimulating 
angiogenesis and invasiveness, and 
modulating cell proliferation by 
increasing the expression of growth 
factors such as platelet-derived growth 
factors (PDGFs).5 
Our case was a young woman with no 
previous history of surgery, estrogen 
supplementation, or a family history 
suggestive of such tumors. 
Pathology  
Arising from the myofibroblasts, the 
macroscopic appearance of desmoid 
tumors is firm and rubbery. It is 
characterized by a relatively 
homogenous incised surface of white 
and greyish network of bundles 
resembling scar tissue with relatively 
poor vascularization. Large desmoid 
tumors may undergo mucoid or cystic 
degeneration.6 Histologically, the tumor 
usually has a poorly circumscribed 
pattern and is composed of proliferating 
stellate to spindle cells arranged in long 
fascicles or whorling patterns with bland 
nuclear features. The cells usually show 
no nuclear atypia or hyperchromasia. 
Immunohistochemistry may aid in ruling 
out other possibilities. Desmoid tumors 
stain positive for vimentin and variably 
positive for smooth muscle actin or other 
muscle-specific markers like desmin. 
Beta-catenin is extremely useful in 
distinguishing from other spindle cell 
neoplasms. Nuclear staining for beta-
catenin is positive in at least 80% of 
sporadic desmoids, with some studies 
demonstrating 98% nuclear staining.7 
The differential diagnosis of intra-
abdominal fibromatosis includes 
gastrointestinal stromal tumor (GIST), 
solitary fibrous tumor, inflammatory 
myofibroblastic tumor, sclerosing 
mesenteritis, and retroperitoneal fibrosis 
or an underlying malignancy, such as a 
lymphoma.8 Intra-abdominal desmoids 
are most commonly misdiagnosed as 
gastrointestinal stromal tumors (GIST), 
but the presence of nuclear beta-catenin 
supports a diagnosis of desmoids, 
although a minority of GIST may 
demonstrate some nuclear beta-catenin 
positivity. Additional stains may be used 
to distinguish between these two, such 
as c-KIT or DOG-1 (Discovered On 
GIST-1). c-KIT and DOG-1 are positive 
in GIST, but negative in desmoids, 
though an infiltrate of mast cells within 
desmoids can result in positive c-KIT 
staining pattern. Histologically, 
idiopathic retroperitoneal fibrosis may 
look similar to desmoid tumors, but the 
hyalinized collagen is more prominent 
with a typical lymphoplasmacytic 
infiltrate; they do not stain for beta-
catenin.7  
Desmoid tumors express hormone 
receptors and most of them express 
estrogen receptors β (ERβ) rather than 
estrogen receptor (ERα), making a case 
for hormonal manipulation in their 
management. In our patient, 
immunohistochemistry or genetic 
studies were not done due to financial 
constraints.  
Clinical presentation 
Patients with intra-abdominal 
fibromatosis are usually asymptomatic 
in the earlier course of the disease. 
Pelvic fibromatosis may present as 
slowly growing palpable masses, which 
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are asymptomatic initially and often 
mimic ovarian neoplasms.6 In advanced 
disease, patients complain of pain, 
discomfort, constipation, vomiting, 
abdominal mass, weight loss, and 
symptoms due to organ compression. 
Specific complications reported are 
ureteric stenosis,9,10 ureteric fistula,11 
bowel obstruction,12 and bowel 
perforation.13 Our patient initially 
presented with an abdominal mass to 
another hospital but refused 
radiotherapy there. She presented to us 
when there was progressive increase in 
its size and abdominal discomfort. 
Clinical course  
Clinically, desmoid tumors are marked 
by phases of growth and progression, 
stabilization, and sometimes 
spontaneous regression. It is difficult to 
predict the clinical course of desmoid 
disease in any particular patient. 
However, in the context of FAP, it has 
been found that desmoids are the worst 
in young nulliparous women. It has been 
reported that, in over 100 FAP patients 
with desmoid disease, 10% experienced 
complete regression of their tumor and 
7% died from aggressive, unresponsive 
disease; the remaining 83% 
experienced variable growth but were 
not severely affected.14  
Management  
When a desmoid tumor is diagnosed, a 
thorough family history, examination, 
and colonoscopy should be performed 
in order to diagnose or rule out familial 
adenomatous polpyposis.15 Patients 
with FAP and intra-abdominal desmoids 
tend to have more severe disease and 
increased recurrence rates. Even if 
colonoscopy is initially normal, these 
patients are recommended for routine 
surveillance with colonoscopy. 
The management involves various 
options of surgery, radiation, non-
steroidal anti-inflammatory drugs, anti-
estrogens, cytotoxic chemotherapy and 
targeted therapies, which are used 
singly or in combination. Choosing an 
optimal therapy for desmoid tumor is 
difficult. The disease has a varied 
presentation and usually requires a 
multi-modality approach. In addition, 
there are no randomized or prospective 
trials for the different treatment options 
because of its rarity. Whatever 
treatment is chosen, recurrence rates 
are high and range between 30% and 
40%.16  
Surgery  
When feasible, desmoids are treated by 
surgical resection with a wide margin. 
Complete resection of the tumor with 
negative microscopic margins is the 
standard surgical goal. However, the 
disease can recur even with complete 
surgical resection and is not shown to 
affect survival. The overall surgical 
strategy is therefore aimed at an attempt 
at complete removal using function-
preserving approaches to minimize 
major morbidity.16 
The surgical management of intra-
abdominal desmoids requires a 
judicious approach to prevent morbidity. 
The extensive involvement of the 
mesentery limits the extent of resection 
and could predispose to signiﬁcant 
morbidity, including complications of 
bowel ischemia, adhesions, and 
resultant obstruction, and even ﬁstulae 
formation.17 Surgery often involves 
extensive resection, including bowel 
resection and anastomosis, 
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hemicolectomy, enbloc removal of 
ureters and bowel with reanastomosis, 
colostomy or even intestinal transplant.  
Palliative surgery for intra-abdominal 
desmoids is hazardous, with a 
perioperative mortality rate of 10% to 
60% (usually from blood loss), and can 
result in further tumor progression.18 
These observations have led to 
conservative management being 
advocated over initial resection for 
patients with FAP or with large slow 
growing desmoids involving the 
mesentery or encasing vessels and 
organs.19 In the Dutch registry of FAP, 
the outcome of intra-abdominal 
desmoids was similar with a surgical 
versus nonsurgical medical approach 
(absence of progression in 33% versus 
49% at 10-year follow-up).20 However, 
surgical resection is indicated with 
symptomatic disease that involves 
visceral organs that will soon be 
affected functionally and rapidly-growing 
desmoids.  
In our patient, surgery was chosen in 
view of the increasing desmoid size, 
patient discomfort, and the progressive 
bilateral ureteric compression. Although 
our surgical team consisted of a 
gynecologist, gynecologic oncologist, 
surgical oncologist and urologist, 
complete resection of the tumor was not 
possible due to its proximity to the pelvic 
vessels. This case highlights the need 
for a multidisciplinary care team in a 
tertiary set-up to tackle the threateningly 
high morbidity when surgery is 
indicated.  
Radiotherapy  
Desmoid tumors are sensitive to 
radiation and it is an effective primary 
therapeutic option for patients with 
extra-abdominal disease who are not 
good surgical candidates, those who 
decline surgery, and those for whom 
surgical morbidity would be excessive.16 
The recommended dose of radiation for 
definitive therapy is 50–60 Gy in 5–7 
weeks at 1.8–2 Gy per fraction. Earlier 
studies demonstrated that radiotherapy 
alone or surgery combined with 
radiotherapy results in better local 
control (78% and 75%) than surgery 
alone (61%).21 However, a more recent 
study reported that the rate of local 
control between the groups receiving 
only surgery, only radiation, and a 
combination of both was not statistically 
different.22 
In intra-abdominal desmoids, the altered 
anatomy and adherence to the bowel 
can increase radiation toxicity. This 
makes radiation therapy a dangerous 
choice in this location and generally is 
advised as a last resort.  
Neoadjuvant (pre-operative) 
radiotherapy may increase resectability 
and reduce rates of local recurrence in 
extra-abdominal desmoids. However, 
this is not considered standard therapy 
as its usefulness has not been 
confirmed by large prospective 
randomized trials.16 
Medical therapy 
A better understanding of the 
pathogenesis and behavior of desmoid 
tumors has paved the way for systemic 
therapies and a wait-and-watch policy. 
Candidates for systemic therapy include 
patients with extra-abdominal desmoids 
with multiple locoregional recurrences 
despite adequate local therapy, patients 
who have progressed and are no longer 
amenable to surgery or radiotherapy, 
and patients undergoing initial treatment 
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of large intra-abdominal desmoids, 
especially those associated with familial 
adenomatous polyposis.16 
Systemic treatment approaches in 
desmoid tumors include antihormonal 
therapy (tamoxifen, and selective 
estrogen receptor modulators/SERMs), 
non-steroidal anti-inflammatory drugs 
(sulindac, indomethacin), chemotherapy 
(single or combination therapy with 
methotrexate, doxorubicin, dacarbazine, 
vinblastine, and vinorelbine), and 
tyrosine kinase inhibitors (imatinib, see 
Table 1). Even though response rates of 
50% or higher are reported, the true 
objective regression rates with these 
agents are in the range of 10%–15%. 
Another 25% of patients experience 
minor shrinkage or tumor stabilization.18 
The maximum effects are often not 
realized for several months, and the 
evaluation of systemic therapies 
becomes rather complicated, especially 
in a tumor that can have spontaneous 
growth arrest and variable growth 
patterns. 
Tamoxifen: High-dose tamoxifen (120–
200 mg/day) is reported to be more 
effective than lower doses of 10–40 
mg/day.23 However, there are no 
randomized data supporting the 
extended use of higher doses, and the 
risk for secondary neoplasia and deep 
venous thrombosis could be greater with 
its use. In general, the true regression 
rate with tamoxifen is in the 15% to 20% 
range, with another 25% to 30% of 
patients achieving symptomatic 
improvement with stabilization of 
disease, resulting in a clinical benefit 
rate of up to 50%.24 
Non-steroidal anti-inflammatory drugs 
(NSAIDS): Sulindac or indomethacin 
result in a variable response rate of 
37%–57%. However, most of these 
reports are single cases that achieved 
disease stabilization.16  
Cytotoxic chemotherapy: Chemotherapy 
with cytotoxic agents may be an 
appropriate choice for patients with 
rapidly growing tumors or for patients 
who are highly symptomatic. Different 
regimen combinations with doxorubicin, 
liposomal doxorubicin, ifosfamide, and 
methotrexate plus vinca alkaloid have 
been used, producing significant 
responses ranging from 50% to 80% 
(partial responses or stable disease for 
at least 6 months).16 The side-effects of 
this regimen have to be balanced with 
the severity of the disease. 
Targeted therapies:  Imatinib is yet to 
be evaluated for its long-term efficacy. 
In cases with large and difficult-to-
operate desmoids, a trial of neoadjuvant 
imatinib is found to be reasonable 
before surgical resection.16  
Currently, most guidelines for systemic 
therapy recommend a stepwise 
approach, starting with NSAIDs 
(preferably sulindac). If this is not 
effective, hormonal therapy is added, 
most commonly consisting of tamoxifen 
or toremifene. Fast growing desmoid 
tumors not responsive to these agents 
are treated by cytotoxic chemotherapy 
or surgery.25  
Management of vesico-colonic fistula 
The development of vesico-colonic 
fistula occurring either due to the 
disease process or as a complication of 
radiotherapy affected the quality of life in 
our patient. The management of 
vesicoenteric fistulas requires surgical 
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therapy aimed toward resolution of the 
primary process and abnormal 
communication as a single or two-stage 
procedure. However, in debilitated 
patients with reasonable life expectancy, 
a palliative colostomy may be 
considered. In very debilitated or 
unresectable diseases, an expectant 
and supportive medical management 
including conservative treatment with 
intermittent antibacterial treatment may 
be all that is possible.26 In our patient, 
the high morbidity associated with a 
second surgery along with the relentless 
progression of the disease decreased 
enthusiasm for surgical intervention. 
In our case, the size of the tumor and 
the bilateral hydronephrosis with 
increasing patient discomfort prompted 
us to proceed with surgery after a 
patient-shared decision. The operative 
morbidity encountered encourages us to 
explore the possibility of using systemic 
therapy either as a primary or in a 
neoadjuvant setting to reduce tumor 
size when dealing with desmoids 
involving vital structures. Successful 
treatment of hydronephrosis due to 
massive mesenteric fibromatosis by 
using cyclo-oxygenase 2 inhibitors 
without surgical removal of the 
mesenteric fibromatosis has been 
reported. There was modest 
improvement in hydronephrosis and 
mesenteric fibromatosis with long-term 
celecoxib used 200 mg twice daily.27  
Radiotherapy either as a primary 
modality or as an adjunct to surgery in 
intra-abdominal desmoids would require 
a cautious approach.  
Figure 5. Treatment algorithm for desmoid tumors (Adapted from Reference 29) 
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Summary of management of desmoid 
tumors 
The treatment of aggressive 
fibromatosis has evolved over the last 
10 years due to a better understanding 
of the disease. The roles of routine, 
aggressive first-line treatment of 
radiotherapy or surgery have now 
become debatable. There is a 
consensus that aggressive treatments 
that take their indications from 
retrospective studies should be re-
evaluated in the light of new data.28 Most 
guidelines recommend an individualized 
approach in the management of 
desmoid tumors. We have summarized 
the currently available possible 
treatment course in desmoid tumors. 
The flowchart in Figure 5 and the 
strategies in Table 1 provide direction to 
optimizing the treatment of desmoid 
tumors.29 
Table 1 - Treatment strategies for desmoid tumor (adapted from ref. 16). 
Intra-abdominal desmoids 
The Collaborative Group of the 
Americas on Inherited Colon Cancer 
has developed a staging and treatment 
system that stratifies intra-abdominal 
desmoids tumors based on prognosis. 
This staging system integrates size (in 
largest diameter), symptoms, and 
growth rate to predict prognosis and 
determine treatment.14 As described in 
Table 2, small (<10 cm), stable, and 
asymptomatic tumors can be monitored 
(Stage I); small, symptomatic tumors 
should be resected (Stage II), when 
feasible; large (10–20 cm) symptomatic 
or large slow growing (<50% increase in 
6 months) / asymptomatic tumors 
require medical therapy (Stage III); and 
large (>20 cm) or rapidly growing or 
complicated desmoid tumors are likely 
to require radical resection and urgent 
intervention (Stage IV). 
 
Treatment Indication 
Surgery Standard first line-treatment (in many cases), 
moderately effective for symptomatic relapse, not 
routinely recommended in FAP* with abdominal 
desmoids 
Active surveillance Small relapse without functional compromise 
Radiation Medical or technical contraindication for surgery, 
possibly neoadjuvant before surgery 
Tamoxifen and/or nonsteroidal anti-inflammatory 
drugs 
First line in indolent disease if systemic treatment is 
indicated 
Imatinib Second line in indolent or moderately symptomatic 
relapse, possibly neoadjuvant before surgery 
Other agents Case reports on several agents, i.e., interferon-α, 
possibly for young women wishing to avoid 
chemotherapy 
Cytotoxic chemotherapy Aggressive disease, especially intra-abdominal 
presentation, doxorubicin single agent or combinations 
*FAP, Familial adenomatous polyposis 
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Table 2 - Clinical staging of intra-abdominal desmoids (adapted from ref. 3) 
Stage Size Symptoms Growth  Treatment recommendation 
I <10 cm Asymptomatic Stable 
 
Observation +/-NSAIDS 
II 
 
<10 cm Mild symptoms Stable 
 
NSAIDS +/- anti-estrogen drugs, 
resection 
III 
 
10-20 cm Moderate symptoms Slow 
growing 
NSAIDS +/- anti-estrogen drugs, 
Cytotoxic therapy 
IV >20 cm Severe symptoms/complications Rapid 
growing 
Resection 
 
 
Mildly symptomatic = sensation of mass, pain, but no restrictions; moderately symptomatic = sensation of mass, 
pain; restrictive but not hospitalized; severely symptomatic = sensation of mass, pain; restrictive and hospitalized. 
The risk of recurrence after intra-abdominal desmoid excision, especially with FAP, ranges from 50% to 80% and it 
is recommended that surgery be followed by prophylactic sulindac. 
 
 
Conclusions 
The management of desmoid tumors is 
multidisciplinary with the various 
available multimodality treatment 
options. Treatment is based on 
resectability and symptomatology. The 
management of intra-abdominal 
desmoid tumors requires a more 
cautious approach as both surgery and 
radiotherapy can adversely affect 
patient’s survival or quality of life. 
Caution is required at every step of the 
treatment due to the potential morbidity 
of any chosen therapy, be it surgery, 
radiation, or systemic therapy. 
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